Drug Search Results
More Filters [+]

64Cu-SARTATE

Alternative Names: 64Cu-SARTATE
Latest Update: 2024-05-14
Latest Update Note: Clinical Trial Update

Product Description

64Cu-SARTATE is being developed by Cleave Biosciences in patients with known or suspected neuroendocrine tumors and requiring a PET scan. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04438304?term=64Cu-SARTATE&draw=2&rank=1)

Mechanisms of Action: Imaging Agent

Novel Mechanism: No

Modality: Diagnostic Agent

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Cleave Biosciences
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for 64Cu-SARTATE

Countries in Clinic: Australia

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Neuroendocrine Tumors

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

DISCO

P2

Active, not recruiting

Neuroendocrine Tumors

2024-10-01

Recent News Events